M&A Integration Excellence: What Bio-Pharma Companies Need to Know
STUDY OVERVIEW
This benchmarking study was conducted to examine winning bio-pharmaceutical M&A integration strategies to provide field benchmarks, lessons learned insights and best practice observations regarding the strategic combination of biotechnology and pharmaceutical assets to optimize ROI.
Executives involved in the merger and acquisition integration process can use this research to ensure their integration strategy reflects the critical lessons learned that participants shared from scores of bio-pharma integrations.
KEY TOPICS
- Structure for Integration
- Pre-Integration Planning Activities
- Integration Risk Management
- Integration Functional Excellence
- Communications Excellence
- Understanding & Managing Cultural Issues
- Post-Deal Closure Integration Activities
- Trends in M&A Integration
- Integration Lessons Learned
KEY METRICS
- Industry Integration Functional Efficacy
- Efficacy of Integration Structural Approaches
- Integration Planning Initiation
- Pre-Integration Planning Activity Efficacy
- Integration Planning Activity Resource Intensity
- Integration Risk-Assessment Factor Importance
- Integration Approach Assessments
- Post-Deal Closure Integration Ownership
- Time to Integration Stability By Organization Size
- Performance Indicators for Integration Performance Measurement
- M&A Activity Horizon
SAMPLE KEY FINDINGS
- Integration structure should reflect the acquired assets & business objectives
- Communications excellence is a foundation for succesful integration
- Understanding and managing cultural issues is vital to assessing and executing successful integration
METHODOLOGY
| The data for this benchmarking study was collected utilizing an online survey instrument and several deep-dive executive interviews. Bio-pharma integration leaders and senior staff from 26 pharmaceutical and biotechnology companies participated in this research. |
Business Operations > Mergers and Acquisitions d
Industries Profiled:
Medical Device; Pharmaceutical; Biotech; Health Care
Companies Profiled:
3M Pharmaceuticals; Takeda Pharmaceuticals; Solvay Pharmaceuticals; SIRO Clinpharm; QLT Inc.; Pfizer; Nizhpharm; Merial; Medtrina; Lilly; Kimble Chase; Johnson & Johnson Healthcare Systems; Indoco; Incite World; Heel; Eisai; Covidien; Coloplast; Baxter Healthcare; ATG; Alexza Pharmaceuticals; Allergan; Absolute Science; Abbott Laboratories
Related Research:
M&A Integration Excellence: What Bio-Pharma Companies Need to Know
 |
STUDY OVERVIEW
This benchmarking study was conducted to examine winning bio-pharmaceutical M&A integration strategies to provide field benchmarks, lessons learned insights and best practice observations regarding the strategic combination of biotechnology and pharmaceutical assets to optimize ROI... (ID POP-224)
Companies Profiled: 3M Pharmaceuticals, Takeda Pharmaceuticals, Solvay Pharmaceuticals, SIRO Clinpharm, more ...
Price: $7000.00 Free Excerpt Available
| |
Merger & Acquisition Integration Excellence
 |
Create superior business growth and value for stakeholders by mastering the five key areas of integration: Business Development; Integration Planning; Culture & Personnel Management; Sales, Marketing & Customer Service; Technology & Systems... (ID OP-73)
Companies Profiled: AstraZeneca; AT Kearney; Bell Atlantic; Boeing; Case Technologies; Chrysler; Cisco Systems; Citigroup; Coca-Cola; DaimlerChrysler; DuPont; EDS; Exxon Mobil; General Electric; GE Capital; GlaxoSmithKline; GTE; Honeywell; IBM; Intel; Johnson & Johnson; Kaiser Permanente; Lockheed Martin; Lucent Technologies; Motorola; Novartis; Phillips; Prudential; SBC Communications; Solectron; Sprint; Synopsys; The Thomson Corporation; Tyco; Verizon Wireless; Viacom; Wells Fargo; Yahoo, Sanofi-aventis
Price: $4000.00 Free Excerpt Available
| |
|